Masaru Matsuda - 02 Nov 2026 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

SEC form
4
Accepted by SEC
04 Nov 2026, 18:38:58 UTC
Prior SEC filing
18 Sep 2026
Source filing
View source filing
Filing notes and source

Key filing fact

Masaru Matsuda filed Form 4 for Arcutis Biotherapeutics, Inc. (ARQT) on 04 Nov 2026.

Key facts

  • This page summarizes Masaru Matsuda's Form 4 filing for Arcutis Biotherapeutics, Inc. (ARQT).
  • 4 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 04 Nov 2026, 18:38.

Change

  • Previous filing in this sequence was filed on 18 Sep 2026.
  • Current net transaction value: -$1,411,513.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001798679 Primary reporting owner

Matsuda Masaru

Relationship
EVP, Chief Legal Officer

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARQT transaction

Common Stock

Sale

Transaction value
-$38,841
Shares
-1,219
Change %
-1.1%
Price
$31.86
Shares after
111,289
Date
02 Nov 2026
Ownership
Direct
Footnotes
F1, F2
ARQT transaction

Common Stock

Options Exercise

Transaction value
Shares
+40,000
Change %
+36%
Price
$3.64*
Shares after
151,289
Date
04 Nov 2026
Ownership
Direct
Footnotes
F3
ARQT transaction

Common Stock

Sale

Transaction value
-$1,372,672
Shares
-40,000
Change %
-26%
Price
$34.32
Shares after
111,289
Date
04 Nov 2026
Ownership
Direct
Footnotes
F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARQT transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-40,000
Change %
-23%
Price
$0.000000*
Shares after
136,000
Date
04 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
40,000
Exercise price
$3.64
Footnotes
F3, F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

Footnote F2

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $31.57 to $32.23, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F3

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 5, 2026, by the Reporting Person, with a plan end date of September 1, 2027.

Footnote F4

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $34.00 to $37.7966, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F5

1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .